Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

JMP Securities Maintains Market Outperform on Pardes Biosciences, Lowers Price Target to $5

Author: Benzinga Newsdesk | March 15, 2023 08:13am
JMP Securities analyst Roy Buchanan maintains Pardes Biosciences (NASDAQ:PRDS) with a Market Outperform and lowers the price target from $9 to $5.

Posted In: PRDS

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist